Opt In to the ALS Metabolomics Study
We believe the course of ALS can be changed in a patient if we knew where the patient was in the course of the disease.
Dr. Robert Naviaux developed an ALS Metabolomic Signature using five serum markers. We are conducting a Metabolomic Signature Study to further classify ALS patients to provide personalized and precision medicine.
Over 5,000 people are diagnosed annually with amyotrophic lateral sclerosis (ALS) and 330,000 people are living with the disease. You can help!
Help NDR fund novel research to bring that number to zero.
Science
ALS, or amyotrophic lateral sclerosis, is a progressive neurodegenerative disease that attacks brain and spinal cord nerve cells.
The term amyotrophic originates in the Greek language and can be translated to "There is no muscle nourishment."
When a muscle is deprived of its neural connection, it "atrophies" or deteriorates.
The term "lateral" refers to the areas of a person's spinal cord that contain portions of the nerve cells that signal and control the muscles.
As neural cells deteriorate, scarring or hardening ("sclerosis") occurs, resulting in the loss of muscle use.
Opt In to the Metabolomic study or donate a kit to an ALS patient
Opt In requires purchase of two kits. One is used at enrollment and the second in 3 months. You will get 2 shipments.
*Please donate what you can. $379 buys one kit, $758 enrolls a patient into the study. Even $10 gets us started to help an ALS patient.
